Reviewing BioCryst Pharmaceuticals Inc. (BCRX)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Both BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are each others competitor in the Biotechnology industry. Thus the compare of their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings & Valuation

Demonstrates BioCryst Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 represents BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)s net margins, return on assets and return on equity.

Volatility and Risk

A 2.02 beta means BioCryst Pharmaceuticals Inc.s volatility is 102.00% more than Standard and Poors 500s volatility. Brainstorm Cell Therapeutics Inc.s 1.19 beta is the reason why it is 19.00% more volatile than Standard and Poors 500.

Liquidity

1.8 and 1.8 are the respective Current Ratio and a Quick Ratio of BioCryst Pharmaceuticals Inc. Its rival Brainstorm Cell Therapeutics Inc.s Current and Quick Ratios are 1 and 1 respectively. BioCryst Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for BioCryst Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

BioCryst Pharmaceuticals Inc.s average price target is $16, while its potential upside is 580.85%. Meanwhile, Brainstorm Cell Therapeutics Inc.s average price target is $9, while its potential upside is 147.25%. Based on the analysts view we can conclude, BioCryst Pharmaceuticals Inc. is looking more favorable than Brainstorm Cell Therapeutics Inc.

Institutional & Insider Ownership

BioCryst Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. has shares owned by institutional investors as follows: 98.7% and 11.4%. Insiders owned roughly 0.2% of BioCryst Pharmaceuticals Inc.s shares. Comparatively, Brainstorm Cell Therapeutics Inc. has 0.6% of its share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year BioCryst Pharmaceuticals Inc. had bearish trend while Brainstorm Cell Therapeutics Inc. had bullish trend.

Summary

BioCryst Pharmaceuticals Inc. beats on 7 of the 12 factors Brainstorm Cell Therapeutics Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Link:
Reviewing BioCryst Pharmaceuticals Inc. (BCRX)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly